Compare Stocks Compare stocks with our powerful stock comparison tool. Analyze fundamentals, price performance, and key financial indicators to make informed investment decisions. Our tool lets you compare up to ten stocks side by side based on Performance Charts, Price & Volume, MarketRank™, Analyst Ratings, Sales & Book Value, Profitability & Earnings, Dividends, Debt, Ownership, Headlines, and more. Simply enter up to ten stock symbols (e.g., BAC, JPM, WFC, C, GS) to get started and uncover top investment opportunities. Stocks to Compare Sections All Sections Selected Performance Chart Price & Volume MarketRank Analyst Ratings Sales & Book Value Profitability & Earnings Dividends Debt Ownership Miscellaneous Headlines About Compare NASDAQ:BEAM NASDAQ:CPRX NASDAQ:DYN NASDAQ:VERV On This Page Performance ChartPrice & VolumeMarketRank™Analyst RatingsSales & Book ValueProfitability & EarningsDividendsDebtOwnershipMiscellaneousHeadlinesAbout Comparison Ideas Stock Ideas Comparative Price Performance Over Time1 day7 days30 days90 days365 daysCompare Price & VolumeCompanyCurrent Price50-Day Moving Average52-Week RangeMarket CapBetaAvg. VolumeToday's VolumeBEAMBeam Therapeutics$32.68-8.8%$31.72$15.60▼$38.26$3.69B2.182.47 million shs2.83 million shsCPRXCatalyst Pharmaceuticals$31.47$31.24$19.05▼$32.56$3.85B0.741.88 million shs1.35 million shsDYNDyne Therapeutics$23.42-3.5%$19.24$8.24▼$25.00$4.01B1.062.24 million shs1.51 million shsVERVVerve Therapeutics$11.13$11.13$3.89▼$11.41$992.13M2.234.91 million shsN/A(Almost) Everything You Need To Know About The EV MarketLooking to profit from the electric vehicle mega-trend? Click the link to see our list of which EV stocks show the most long-term potential.Get This Free ReportCompare Price PerformanceCompany1-Day Performance7-Day Performance30-Day Performance90-Day Performance1-Year PerformanceBEAMBeam Therapeutics-8.77%-6.06%+10.82%+19.14%+52.28%CPRXCatalyst Pharmaceuticals0.00%+0.06%+0.41%+26.18%+45.49%DYNDyne Therapeutics-3.50%+1.52%+32.54%+25.37%+163.74%VERVVerve Therapeutics0.00%0.00%0.00%0.00%+0.36%Compare Price & VolumeCompanyCurrent Price50-Day Moving Average52-Week RangeMarket CapBetaAvg. VolumeToday's VolumeBEAMBeam Therapeutics$32.68-8.8%$31.72$15.60▼$38.26$3.69B2.182.47 million shs2.83 million shsCPRXCatalyst Pharmaceuticals$31.47$31.24$19.05▼$32.56$3.85B0.741.88 million shs1.35 million shsDYNDyne Therapeutics$23.42-3.5%$19.24$8.24▼$25.00$4.01B1.062.24 million shs1.51 million shsVERVVerve Therapeutics$11.13$11.13$3.89▼$11.41$992.13M2.234.91 million shsN/A(Almost) Everything You Need To Know About The EV MarketLooking to profit from the electric vehicle mega-trend? Click the link to see our list of which EV stocks show the most long-term potential.Get This Free ReportCompare Price PerformanceCompany1-Day Performance7-Day Performance30-Day Performance90-Day Performance1-Year PerformanceBEAMBeam Therapeutics-8.77%-6.06%+10.82%+19.14%+52.28%CPRXCatalyst Pharmaceuticals0.00%+0.06%+0.41%+26.18%+45.49%DYNDyne Therapeutics-3.50%+1.52%+32.54%+25.37%+163.74%VERVVerve Therapeutics0.00%0.00%0.00%0.00%+0.36%Compare Analyst ForecastsCompanyConsensus Rating ScoreConsensus RatingConsensus Price Target% Upside from Current PriceBEAMBeam Therapeutics 2.73Moderate Buy$46.8543.35% UpsideCPRXCatalyst Pharmaceuticals 2.56Moderate Buy$32.001.68% UpsideDYNDyne Therapeutics 2.86Moderate Buy$34.1745.89% UpsideVERVVerve Therapeutics 0.00N/AN/AN/ACurrent Analyst Ratings BreakdownLatest VERV, DYN, BEAM, and CPRX Analyst RatingsDateCompanyBrokerageActionRatingPrice TargetDetails7/8/2026BEAMBeam Therapeutics Bank of AmericaSubscribe to MarketBeat All Access for the firm's recommendation accuracy ratingReiterated RatingBuy$47.007/7/2026BEAMBeam Therapeutics HC WainwrightSubscribe to MarketBeat All Access for the firm's recommendation accuracy ratingReiterated RatingBuy$80.006/26/2026DYNDyne Therapeutics TD CowenSubscribe to MarketBeat All Access for the firm's recommendation accuracy ratingInitiated CoverageBuy6/3/2026CPRXCatalyst Pharmaceuticals Weiss RatingsSubscribe to MarketBeat All Access for the firm's recommendation accuracy ratingUpgradeBuy (B-) ➝ Buy (B)5/28/2026CPRXCatalyst Pharmaceuticals HC WainwrightSubscribe to MarketBeat All Access for the firm's recommendation accuracy ratingDowngradeBuy ➝ Neutral$35.00 ➝ $31.505/21/2026BEAMBeam Therapeutics HC WainwrightSubscribe to MarketBeat All Access for the firm's recommendation accuracy ratingReiterated RatingBuy$80.005/18/2026CPRXCatalyst Pharmaceuticals Zacks ResearchSubscribe to MarketBeat All Access for the firm's recommendation accuracy ratingDowngradeStrong-Buy ➝ Hold5/15/2026DYNDyne Therapeutics EvercoreSubscribe to MarketBeat All Access for the firm's recommendation accuracy ratingSet Price Target$33.005/13/2026DYNDyne Therapeutics Sanford C. BernsteinSubscribe to MarketBeat All Access for the firm's recommendation accuracy ratingBoost Price TargetMarket Perform$23.00 ➝ $24.005/13/2026BEAMBeam Therapeutics Tudor PickeringSubscribe to MarketBeat All Access for the firm's recommendation accuracy ratingSet Price Target$39.005/13/2026BEAMBeam Therapeutics Sanford C. BernsteinSubscribe to MarketBeat All Access for the firm's recommendation accuracy ratingLower Price TargetOutperform$40.00 ➝ $39.00(Data available from 7/11/2023 forward. View 10+ years of historical ratings with our analyst ratings screener.)Compare Sales & Book ValueCompanyAnnual RevenuePrice/SalesCashflowPrice/CashBook ValuePrice/BookBEAMBeam Therapeutics$139.74M24.06N/AN/A$12.20 per share2.68CPRXCatalyst Pharmaceuticals$588.99M6.54$2.92 per share10.77$7.76 per share4.06DYNDyne TherapeuticsN/AN/AN/AN/A$6.81 per shareN/AVERVVerve Therapeutics$32.33M30.69N/AN/A$5.83 per share1.91Compare Profitability & EarningsCompanyNet IncomeEPSTrailing P/E RatioForward P/E RatioP/E GrowthNet MarginsReturn on Equity (ROE)Return on Assets (ROA)Next Earnings DateBEAMBeam Therapeutics-$79.99M-$0.68N/AN/AN/A-39.66%-29.00%-22.61%8/4/2026 (Estimated)CPRXCatalyst Pharmaceuticals$214.33M$1.7418.0910.220.9637.08%35.76%31.31%8/5/2026 (Estimated)DYNDyne Therapeutics-$446.21M-$3.22N/AN/AN/AN/A-58.28%-46.77%7/27/2026 (Estimated)VERVVerve Therapeutics-$198.71M-$2.11N/AN/AN/A-303.64%-35.81%-27.57%N/ALatest VERV, DYN, BEAM, and CPRX EarningsDateQuarterCompanyConsensus EstimateReported EPSBeat/MissGap EPSRevenue EstimateActual RevenueDetails8/5/2026Q2 2026CPRXCatalyst Pharmaceuticals$0.48N/AN/AN/A$155.79 millionN/A8/4/2026Q2 2026BEAMBeam Therapeutics-$1.1152N/AN/AN/A$16.37 millionN/A7/27/2026Q2 2026DYNDyne Therapeutics-$0.74N/AN/AN/AN/AN/A5/11/2026Q1 2026DYNDyne Therapeutics-$0.7723-$0.73+$0.0423-$0.73N/AN/A5/7/2026Q1 2026BEAMBeam Therapeutics-$1.0278-$0.91+$0.1178-$0.91$10.98 million$31.74 millionCompare DividendsCompanyAnnual PayoutDividend Yield5-Year Annualized Dividend GrowthPayout RatioYears of Consecutive GrowthBEAMBeam TherapeuticsN/AN/AN/AN/AN/ACPRXCatalyst PharmaceuticalsN/AN/AN/AN/AN/ADYNDyne TherapeuticsN/AN/AN/AN/AN/AVERVVerve TherapeuticsN/AN/AN/AN/AN/ACompare DebtCompanyDebt-to-Equity RatioCurrent RatioQuick RatioBEAMBeam Therapeutics0.0916.9916.99CPRXCatalyst PharmaceuticalsN/A7.106.84DYNDyne Therapeutics0.1719.9219.92VERVVerve TherapeuticsN/A9.849.84Compare OwnershipInstitutional OwnershipCompanyInstitutional OwnershipBEAMBeam Therapeutics99.68%CPRXCatalyst Pharmaceuticals79.22%DYNDyne Therapeutics96.68%VERVVerve Therapeutics97.11%Insider OwnershipCompanyInsider OwnershipBEAMBeam Therapeutics3.80%CPRXCatalyst Pharmaceuticals10.40%DYNDyne Therapeutics9.46%VERVVerve Therapeutics19.30%Compare Miscellaneous StatsCompanyEmployeesShares OutstandingFree FloatOptionableBEAMBeam Therapeutics510102.88 million98.97 millionOptionableCPRXCatalyst Pharmaceuticals80122.42 million109.69 millionOptionableDYNDyne Therapeutics100165.31 million149.68 millionOptionableVERVVerve Therapeutics11089.14 million71.94 millionOptionableVERV, DYN, BEAM, and CPRX HeadlinesRecent News About These CompaniesGoodbye daily statins? VERVE-102 aims to cut LDL cholesterol in one shotJune 8, 2026 | msn.comBig pharma all-in on gene therapy after obesity successMay 31, 2026 | msn.comPCSK9 inhibition via base editing lowers LDL in patients with genetic high cholesterolMay 29, 2026 | healio.comHA one-time experimental treatment might control cholesterol for lifeMay 29, 2026 | msn.comPharmalittle: We’re reading about a Lilly gene therapy for cholesterol, three new Lilly deals, and moreMay 28, 2026 | statnews.comSA gene therapy lowered cholesterol in early trial results. It has a Philly backstory.May 28, 2026 | inquirer.comICan one treatment lower cholesterol and reduce heart attack risk for years?May 26, 2026 | business-standard.comBCan an injection prevent heart attacks? Eli Lilly’s gene-editing therapy cuts LDL cholesterol by 62%May 26, 2026 | indianexpress.comILilly says gene editing therapy cut “bad” cholesterol in early-stage trialMay 26, 2026 | seekingalpha.comSo Far, So Good for PCSK9-Targeting Gene Therapy in HypercholesterolemiaMay 26, 2026 | medpagetoday.comMLilly is looking for its next act beyond the weight-loss boomMay 26, 2026 | msn.comEli Lilly-backed gene-editing therapy cuts ‘bad’ cholesterol by up to 62% in early trialMay 26, 2026 | cnbctv18.comCLilly says gene editing therapy cut bad cholesterol in early-stage trialMay 26, 2026 | msn.comLilly advances gene therapy, snaps up vaccine makers. It’s looking beyond weight lossMay 26, 2026 | msn.comLilly preps for ph. 2 launch after Verve gene editor cuts cholesterol on par with PCSK9 inhibitorsMay 25, 2026 | fiercebiotech.comFIn Vivo Base Editing of PCSK9 with VERVE-102 for HypercholesterolemiaMay 25, 2026 | nejm.orgNEli Lilly says Verve’s gene editor lowers cholesterol levels in early studyMay 25, 2026 | statnews.comSThree Biotechs That Are Top Takeover TargetsMay 18, 2026 | 247wallst.comEuropean Biotechs Developing Next-Generation of Cardiometabolic and Precision Cardiology TherapeuticsApril 14, 2026 | pharmtech.comPStudies test whether gene-editing can fix high cholesterolFebruary 17, 2026 | tribtoday.comTNew MarketBeat Followers Over TimeMedia Sentiment Over Time Top HeadlinesView All HeadlinesMission Control: Floating In SpaceX's Record-Breaking OrbitBy Jeffrey Neal Johnson | June 15, 2026SpaceX Rings the Bell and Shatters Every RecordBy Jeffrey Neal Johnson | June 12, 2026Gravity Check: Houston, SpaceX Has a Valuation ProblemBy Jeffrey Neal Johnson | June 16, 2026The Oil Trade May Not Be Over: 3 Energy Stocks to WatchBy Thomas Hughes | June 21, 2026These 3 Cash-Flow Stocks Give Investors More Than Just Growth PotentialBy Nathan Reiff | July 8, 2026VERV, DYN, BEAM, and CPRX Company DescriptionsBeam Therapeutics NASDAQ:BEAM$32.68 -3.14 (-8.77%) Closing price 07/10/2026 04:00 PM EasternExtended Trading$32.52 -0.16 (-0.47%) As of 07/10/2026 07:58 PM Eastern Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Massive. Learn more.Beam Therapeutics Inc., a biotechnology company, engages in the development of precision genetic medicines for patients suffering from serious diseases in the United States. It develops BEAM-101 for the treatment of sickle cell disease or beta-thalassemia; and BEAM-302, a liver-targeting LNP formulation to treat severe alpha-1 antitrypsin deficiency; BEAM-201, an anti-CD7 CAR-T product candidate, which is in Phase 1/2 clinical trials for the treatment of refractory T-cell acute lymphoblastic leukemia/T cell lymphoblastic lymphoma; and BEAM-301, a liver-targeting LNP formulation for the treatment of glycogen storage disease 1a. The company has research collaboration agreement with Pfizer Inc., focus on in vivo base editing programs for targets rare genetic diseases of the liver, muscle, and central nervous system; Apellis Pharmaceuticals to conduct preclinical research on target specific genes within the complement system in various organs, including the eye, liver, and brain; Verve Therapeutics, Inc., for cardiovascular disease treatments; Sana Biotechnology, Inc., to research, develop, and commercialize rights to CRISPR Cas12b for cell therapy programs; and Orbital Therapeutics design RNA for the prevention, treatment or diagnosis of human disease. Beam Therapeutics Inc. was incorporated in 2017 and is based in Cambridge, Massachusetts.Catalyst Pharmaceuticals NASDAQ:CPRX$31.47 0.00 (0.00%) Closing price 07/10/2026 04:00 PM EasternExtended Trading$31.48 +0.02 (+0.05%) As of 07/10/2026 07:55 PM Eastern Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Massive. Learn more.Catalyst Pharmaceuticals, Inc., a commercial-stage biopharmaceutical company, focuses on developing and commercializing therapies for people with rare debilitating, chronic neuromuscular, and neurological diseases in the United States. It offers Firdapse, an amifampridine phosphate tablets for the treatment of patients with lambert-eaton myasthenic syndrome (LEMS); and Ruzurgi for the treatment of pediatric LEMS patients. The company develops Firdapse for the treatment of MuSK antibody positive myasthenia gravis and spinal muscular atrophy type. It has license agreements with BioMarin Pharmaceutical Inc.; and collaboration and license agreement with Endo Ventures Limited for the development and commercialization of generic Sabril tablets. The company was founded in 2002 and is based in Coral Gables, Florida.Dyne Therapeutics NASDAQ:DYN$23.42 -0.85 (-3.50%) Closing price 07/10/2026 04:00 PM EasternExtended Trading$23.00 -0.43 (-1.81%) As of 07/10/2026 06:34 PM Eastern Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Massive. Learn more.Dyne Therapeutics, Inc., a clinical-stage muscle disease company, operates as a biotechnology company that focuses on advancing therapeutics for genetically driven muscle diseases in the United States. It is developing a portfolio of muscle disease therapeutics, including programs in myotonic dystrophy type 1; duchenne muscular dystrophy; and facioscapulohumeral dystrophy, as well as rare skeletal muscle, and cardiac and metabolic muscle diseases using its FORCE platform that delivers disease-modifying therapeutics. Dyne Therapeutics, Inc. was incorporated in 2017 and is headquartered in Waltham, Massachusetts.Verve Therapeutics NASDAQ:VERVVerve Therapeutics, Inc., a clinical stage genetic medicines company, engages in developing gene editing medicines for patients to treat cardiovascular diseases in the United States. The company's lead product candidate is VERVE-101, a single-course gene editing treatment that permanently turns off the PCSK9 gene in the liver; and VERVE-102, a product candidate that targets the PCSK9 gene for the treatment of HeFH. It engages in the development of ANGPTL3 program to permanently turn off the ANGPTL3 gene in the liver. It has a collaboration and license agreement with Beam Therapeutics Inc.; a development and option agreement with Acuitas Therapeutics, Inc.; and a Cas9 license agreement with The Broad Institute and the President and Fellows of Harvard College. The company was formerly known as Endcadia, Inc. and changed its name to Verve Therapeutics, Inc. in January 2019. Verve Therapeutics, Inc. was incorporated in 2018 and is headquartered in Cambridge, Massachusetts. More Stock Comparisions from MarketBeat Stock Comparison Ideas (A-K)5GAgricultureAirlineAmerica FirstApparelArtificial IntelligenceAutomotiveBankBiotechBitcoinBlockchainBlue ChipCanadianCannabisCasinoChatGPTChineseCloud StorageCryptocurrencyCybersecurityDefenseDividendDow 30DroneEcommerceElectric VehiclesEnergyEntertainmenteSportsEV ChargingFertilizerFlying CarGoldGroceryGrowthHealthcareHigh DividendHotelStock Comparison Ideas (L-Z)Large CapLeisureLithiumMade In AmericaMagnificent SevenMega CapMemeMetaverseMid CapMiningMusic IndustryNanotechnologyNFTNuclear EnergyOilPharmaceuticalQuantum ComputingRenewable EnergyRestaurantRetailSemiconductorSilverSocial MediaSolarSpaceTechnologyTelecomToyUraniumUtilityVideo GameVirtual RealityWallStreetBets More Stock Ideas from MarketBeat Stock Lists 5G Stocks Biotech Stocks Blue Chip Stocks DOW 30 Stocks FAANG Stocks Gold Stocks Large Cap Stocks Lumber Stocks Marijuana Stocks Micro Cap Stocks Oil Stocks REITs Small Cap Stocks SPACs Travel Stocks Trillion Dollar Stocks Water Stocks Warren Buffett Stocks Low Priced Stocks Penny Stock List Popular Penny Stocks Top Stocks Today Stocks on Sale Stocks Under $0.05 Stocks Under $0.10 Stocks Under $0.25 Stocks Under $0.50 Stocks Under $1 Stocks Under $2 Stocks Under $3 Stocks Under $5 Stocks Under $10 Stocks Under $20 Stocks Under $30 Stocks Under $50 Stocks By Exchange NASDAQ Stocks NYSE Stocks NYSEAMERICAN Stocks NYSEARCA Stocks NYSEMKT Stocks OTCMKTS Stocks TSX Stocks TSXV Stocks LSE Stocks BATS Stocks Latest Stock Ideas MarketBeat Week in Review – 07/06 - 07/10 Why WD-40 Is Proving Great Businesses Never Go Out of Style Rocket Lab’s Stock Drop Comes With a Bullish Twist Power Struggle: Wolfspeed Sues Navitas Over AI Chips Pushing the Edge: Super Micro Computer Reboots the AI Landscape Micron's $250 Billion Bet Could Reshape the AI Memory Race AeroVironment Flies Under Wall Street’s Radar Toward a $4 Billion Target IQM's Nasdaq Debut Could Change the Quantum Race for D-Wave Unlock superior investment research and tools. Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools and reports. Get MarketBeat All Access MarketBeat All Access Features Best-in-Class Portfolio Monitoring Get personalized stock ideas. Compare portfolio to indices. Check stock news, ratings, SEC filings, and more. Stock Ideas and Recommendations See daily stock ideas from top analysts. Receive short-term trading ideas from MarketBeat. Identify trending stocks on social media. Advanced Stock Screeners and Research Tools Use our seven stock screeners to find suitable stocks. Stay informed with MarketBeat's real-time news. Export data to Excel for personal analysis. Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Email Address Required Your Password: Password Required Log In Email Me a Login Link or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Please enter your email address. Please enter a valid email address Choose a Password: Please enter your password. Your password must be at least 8 characters long and contain at least 1 number, 1 letter, and 1 special character. Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.
